228 related articles for article (PubMed ID: 35678771)
1. Effectiveness and Safety of Tofacitinib in Canadian Patients With Rheumatoid Arthritis: Primary Results From a Prospective Observational Study.
Haraoui B; Khraishi M; Choquette D; Lisnevskaia L; Teo M; Kinch C; Galos C; Roy P; Gruben D; Woolcott JC; Vaillancourt J; Sampalis JS; Keystone EC;
Arthritis Care Res (Hoboken); 2023 Feb; 75(2):240-251. PubMed ID: 35678771
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.
Lee EB; Yamanaka H; Liu Y; Tsai WC; Chen C; Kwok K; Yoo HJ; Llamado LJ; Wang L; Luo Y; Sugiyama N; Tanaka Y
Int J Rheum Dis; 2019 Jun; 22(6):1094-1106. PubMed ID: 30900375
[TBL] [Abstract][Full Text] [Related]
3. Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: An open-label randomized controlled trial.
Khan MM; Ahmed S; Hasan Sajib MK; Morshed AA; Mahbub-Uz-Zaman K; Haq SA
Int J Rheum Dis; 2023 Sep; 26(9):1729-1736. PubMed ID: 37377385
[TBL] [Abstract][Full Text] [Related]
4. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
[TBL] [Abstract][Full Text] [Related]
5. Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
Bird P; Hall S; Nash P; Connell CA; Kwok K; Witcombe D; Thirunavukkarasu K
RMD Open; 2019; 5(1):e000742. PubMed ID: 30886732
[TBL] [Abstract][Full Text] [Related]
6. Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance.
Kuwana M; Sugiyama N; Momohara S; Atsumi T; Takei S; Tamura N; Harigai M; Fujii T; Matsuno H; Takeuchi T; Yamamoto K; Takasaki Y; Tanigawa M; Endo Y; Hirose T; Morishima Y; Yoshii N; Mimori T; Takagi M
Mod Rheumatol; 2024 Feb; 34(2):272-286. PubMed ID: 37405710
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6.
van Vollenhoven RF; Lee EB; Fallon L; Zwillich SH; Wilkinson B; Chapman D; DeMasi R; Keystone E
Arthritis Care Res (Hoboken); 2019 Jan; 71(1):71-79. PubMed ID: 29696833
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies.
Dikranian AH; Gonzalez-Gay MA; Wellborne F; Álvaro-Gracia JM; Takiya L; Stockert L; Paulissen J; Shi H; Tatulych S; Curtis JR
RMD Open; 2022 May; 8(1):. PubMed ID: 35577477
[TBL] [Abstract][Full Text] [Related]
9. Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria.
Smolen JS; Aletaha D; Gruben D; Zwillich SH; Krishnaswami S; Mebus C
Arthritis Rheumatol; 2017 Apr; 69(4):728-734. PubMed ID: 27907269
[TBL] [Abstract][Full Text] [Related]
10. Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
Kaine J; Tesser J; Takiya L; DeMasi R; Wang L; Snyder M; Soma K; Fan H; Bandi V; Wollenhaupt J
Clin Rheumatol; 2020 Jul; 39(7):2127-2137. PubMed ID: 32048083
[TBL] [Abstract][Full Text] [Related]
11. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis.
Li ZG; Liu Y; Xu HJ; Chen ZW; Bao CD; Gu JR; Zhao DB; An Y; Hwang LJ; Wang L; Kremer J; Wu QZ
Chin Med J (Engl); 2018 Nov; 131(22):2683-2692. PubMed ID: 30425195
[TBL] [Abstract][Full Text] [Related]
13. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Yamanaka H; Tanaka Y; Takeuchi T; Sugiyama N; Yuasa H; Toyoizumi S; Morishima Y; Hirose T; Zwillich S
Arthritis Res Ther; 2016 Jan; 18():34. PubMed ID: 26818974
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Disease Activity Metrics in a Methotrexate Withdrawal Study among Patients with Rheumatoid Arthritis Treated with Tofacitinib plus Methotrexate.
Fleischmann R; Haraoui B; Buch MH; Gold D; Sawyerr G; Shi H; Diehl A; Lee K
Rheumatol Ther; 2023 Apr; 10(2):375-386. PubMed ID: 36534208
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
Fleischmann R; Mease PJ; Schwartzman S; Hwang LJ; Soma K; Connell CA; Takiya L; Bananis E
Clin Rheumatol; 2017 Jan; 36(1):15-24. PubMed ID: 27734232
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.
Wollenhaupt J; Silverfield J; Lee EB; Curtis JR; Wood SP; Soma K; Nduaka CI; Benda B; Gruben D; Nakamura H; Komuro Y; Zwillich SH; Wang L; Riese RJ
J Rheumatol; 2014 May; 41(5):837-52. PubMed ID: 24692527
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry.
Thorne C; Bensen WG; Choquette D; Chow A; Khraishi M; Atkins CJ; Kelsall JT; Lehman AJ; Shawi M; Khalil H; Nantel F; Rampakakis E; Sampalis JS; Otawa S
Arthritis Care Res (Hoboken); 2014 Aug; 66(8):1142-51. PubMed ID: 24470077
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials.
Strand V; Lee EB; Yazici Y; Dikranian A; Wilkinson B; Takiya L; Zang C; Bananis E; Bergman MJ
Clin Rheumatol; 2018 Aug; 37(8):2043-2053. PubMed ID: 29656373
[TBL] [Abstract][Full Text] [Related]
20. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials.
Wright GC; Mysler E; Kwok K; Cadatal MJ; Germino R; Yndestad A; Kinch CD; Ogdie A
Rheumatol Ther; 2024 Jul; ():. PubMed ID: 38958913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
